A report card to grade Helicobacter pylori therapy

被引:414
作者
Graham, David Y.
Lu, Hong
Yamaoka, Yoshio
机构
[1] Michael E DeBakey VA Med Ctr, Dept Med, Houston, TX 77030 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Digest Dis, Renji Hosp,Dept Gastroenterol, Shanghai 200030, Peoples R China
关键词
D O I
10.1111/j.1523-5378.2007.00518.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Helicobacter pylori causes a serious bacterial infectious disease, and the expectations of therapy should reflect this fact. increasing antibiotic resistance, especially to clarithromycin, has significantly undermined the effectiveness of legacy triple therapy consisting of a proton pump inhibitor, clarithromycin, and amoxicillin. Current cure rates are consistently below 80% intention-to-treat, the accepted threshold separating acceptable from unacceptable treatment results. Grading clinical studies into effectiveness categories using prespecified criteria would allow clinicians to objectively identify and compare regimens. We offer a therapy report card similar to that used to grade the performance of school children. The intention-to-treat cure rate categories are: For unacceptable (<= 80%), D or poor (81-84%), C or fair (85-89%), B or good (90-95%), and A or excellent (95-100%). The category of "excellent" is based on the cure rates expected with other prevalent bacterial infectious diseases. We propose that only therapies that score "excellent" (grade = A) should be prescribed. Regimens scoring as B or good" can be used if "excellent" results are not obtainable. In most regions legacy triple therapy should be abandoned as unacceptable. Quadruple therapy and sequential therapy are reasonable alternatives for initial therapy.
引用
收藏
页码:275 / 278
页数:4
相关论文
共 36 条
[1]   Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease:: Results of two double-blind, randomized studies [J].
Bochenek, WJ ;
Peters, S ;
Fraga, PD ;
Wang, WJ ;
Mack, ME ;
Osato, MS ;
El-Zimaity, HMT ;
Davis, KD ;
Graham, DY .
HELICOBACTER, 2003, 8 (06) :626-642
[2]  
Boixeda D, 2003, REV ESP ENFERM DIG, V95, P206
[3]   Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication:: A multicenter randomized trial [J].
Calvet, X ;
Ducons, J ;
Bujanda, L ;
Bory, F ;
Montserrat, A ;
Gisbert, JP .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (08) :1696-1701
[4]   What is the optimal length of proton pump inhibitor-based triple therapies for H-pylori?: A cost-effectiveness analysis [J].
Calvet, X ;
Gené, E ;
López, T ;
Gisbert, JP .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (07) :1067-1076
[5]   The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme:: a prospective, randomised study [J].
De Francesco, V ;
Zullo, A ;
Hassan, C ;
Della Valle, N ;
Pietrini, L ;
Minenna, MF ;
Winn, S ;
Monno, R ;
Stoppino, V ;
Morini, S ;
Panella, C ;
Ierardi, E .
DIGESTIVE AND LIVER DISEASE, 2004, 36 (05) :322-326
[6]   Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia [J].
De Francesco, V ;
Della Valle, N ;
Stoppino, V ;
Amoruso, A ;
Muscatiello, N ;
Panella, C ;
Ierardi, E .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (09) :993-998
[7]  
Della Monica P, 2002, ALIMENT PHARM THER, V16, P1269
[8]   A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori [J].
Fennerty, MB ;
Kovacs, TOG ;
Krause, R ;
Haber, M ;
Weissfeld, A ;
Siepman, N .
ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (15) :1651-1656
[9]   Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children:: a randomized trial [J].
Francavilla, R ;
Lionetti, E ;
Castellaneta, SP ;
Magistà, AM ;
Boscarelli, G ;
Piscitelli, D ;
Amoruso, A ;
Di Leo, A ;
Miniello, VL ;
Francavilla, A ;
Cavallo, L ;
Ierardi, E .
GASTROENTEROLOGY, 2005, 129 (05) :1414-1419
[10]   Influence of CYP2C19 polymorphism and helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection [J].
Furuta, T ;
Sagehashi, Y ;
Shirao, N ;
Sugimoto, M ;
Nakamura, A ;
Kodaira, M ;
Kenmotsu, K ;
Nagano, M ;
Egashira, T ;
Ueda, K ;
Yoneyama, M ;
Ohashi, K ;
Ishizaki, T ;
Hishida, A .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2005, 3 (06) :564-573